Press Release Details

Cerus Corporation Appoints Vice President of Legal Affairs

July, 07 1999

CONCORD, Calif., July 7 /PRNewswire/ -- Cerus Corporation (Nasdaq: CERS), a leading developer of systems to prevent the transmission of diseases through blood transfusions, announced today the appointment of Howard G. Ervin, age 51, as Vice President, Legal Affairs.

Prior to joining Cerus, Mr. Ervin was a partner at the law firm of Cooley Godward LLP where he specialized in corporate and technology transactions, principally for life sciences companies. Mr. Ervin holds a BA from Harvard College and a JD from the University of Chicago.

"Howard worked with us when we founded Cerus and has made valuable contributions at virtually every important step we have taken. He is part of the Cerus family," said Cerus President and Chief Executive Officer Stephen Isaacs. "As we enter late-stage clinical trials, we feel it is important to have someone with Howard's skills and experience at Cerus full time. We are extremely pleased to welcome him to the team."

Cerus Corporation is developing proprietary systems to improve the safety of blood products through the inactivation of viruses, bacteria and other pathogens. Programs for platelets, plasma and red blood cells intended for transfusion are currently in clinical trials. Cerus is also developing a system as an up-front method to treat source plasma used for fractionation into various plasma products. Cerus has collaboration agreements with Baxter Healthcare and the Consortium for Plasma Science.

Statements in this news release regarding product development and clinical development are forward-looking statements that involve risks and uncertainties. Actual results could differ materially from the above forward-looking statements as a result of certain factors, including the uncertainty of the timing and results of any clinical trials, regulation by the FDA, the uncertainty of replication of animal data in humans, the uncertainty of market acceptance of any products, competitive conditions, the uncertainty of future financing and other factors discussed in the company's 1997 Annual Report on Form 10-K.

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600